Corindus Vascular Robotics

Corindus said new motion automations have received FDA clearance for use in coronary and peripheral robotic-assisted procedures.

Welcome to Episode 18 of The Robot Report Podcast, which brings conversations with robotics innovators straight to you. Join us every week for discussions with leading roboticists, innovative robotics companies, and other key members of the robotics community. Listeners can subscribe to The Robot Report Podcast on Amazon Music, Apple Podcasts, SoundCloud, Spotify, Google Play, and…

The range of surgical procedures that robots can assist is widening, even as systems become more specialized.

Doctor have now used the CorPath GRX system in a successful brain surgery and to conduct multiple remote surgeries, advancing the state of robot-assisted procedures.

A cardiac surgeon in India and one in the U.S. discuss promising developments and remaining challenges around robot-assisted telesurgery.

Corindus Vascular Robotics, whose CorPath GRX has FDA approval for percutaneous coronary and vascular procedures, will be acquired by Siemens Healthineers.

As robots expand beyond manufacturing, what should developers know about new applications? Here are six examples of robotics needs.

Robotics investments totaled at least $4.3 billion in February 2019 in a steep increase from January, which had about $1.4 billion. In addition, companies reported approximately $3.9 billion worth of acquisitions this past month. Any political or economic jitters have not yet harmed the mood for robot deals. The Robotic Industries Association noted yesterday that robot…

Corindus Vascular Robotics this week said it applied to the U.S. Food and Drug Administration for premarket clearance to use its CorPath GRX robotic surgical platform in neurovascular interventions. The Waltham, Mass.-based company has already received FDA clearance for percutaneous coronary interventions (PCI), which it won in 2016, and for peripheral vascular interventions (PVI), which it won last…

Corindus Vascular Robotics has won clearance from Japan’s Pharmaceutical and Medical Device Agency for its CorPath GRX robotic surgical device. The CorPath GRX vascular robotics platform is designed to assist cardiologists in performing percutaneous coronary interventions (PCI) procedures, including angioplasty and stent placement. Japan is one of the largest markets in the world for PCIs, according to…

Corindus Vascular Robotics inked a private placement deal worth $25 million through the offering of newly-designated Series A convertible preferred stock, with funds slated to support global commercialization of its CorPath GRX robotic surgical system. The Waltham, Mass.-based company will issue shares of Series A convertible preferred stock convertible into 20 million shares of common stock…

Corindus Vascular Robotics has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first automated robotic movement designed for its CorPath GRX platform. Called “Rotate on Retract” (RoR), the proprietary software feature is the first automated robotic movement in the technIQ Series for the CorPath GRX platform. It allows the operator…

Corindus Vascular Robotics (OTC:CVRS) said today it is working with the Mayo Clinic to launch preclinical studies exploring the use of telestenting, a robotic treatment for percutaneous coronary interventions which can be operated by physicians in remote locations. The Waltham, Mass.-based surgical robotics company said that there is a global shortage of PCI-capable operators, and that telestenting…

Corindus Vascular Robotics (OTC:CVRS) today touted the first commercial installation of its CorPath GRx robotic surgical system outside of the US. The CorPath GRX platform, a robot-assisted system for percutaneous coronary interventions such as stenting, was purchased and installed at the Ahmedabad, India’s Apex Heart Institute, the Waltham, Mass.-based company said. Corindus said that it will…

Corindus Vascular Robotics (OTC:CVRS), a Massachusetts-based surgical robotics company, plans to utilize technology that creates 3D images of arteries for evaluating patients. Company officials said they’d employ California-based HeartFlow’s FFRct Analysis in a case series of robotic-assisted percutaneous coronary interventions to evaluate the technology’s role in clinical decision support. The testing will be done at hospitals…

Corindus Vasular Robotics opened its first international CorPath GRX Robotic Center in Tokyo to educate cardiologists on robotic-assisted percutaneous coronary interventions, the company announced today. “The opening of the first international robotic center represents an important milestone in the process of bringing precision vascular robotics to patients and physicians in Japan and around the world,”…

Corindus Vascular Robotics announced the first patient enrollment in a post-market study of its second-generation CorPath GRX System, a robot-assisted system for percutaneous coronary interventions such as stenting. “Enrollment of the first patient in the Precision GRX registry is a major milestone for the company and we look forward to the participation of leading centers…